Cardiovascular toxicity with levetiracetam overdose

Colin B. PageClinical Toxicology Research Group, University of Newcastle, Newcastle, Australia; ;School of Medicine, University of Queensland, Brisbane, Australia; ;Emergency Department, Princess Alexandra Hospital, Brisbane, Australia; Correspondence[email protected]

Ahmed MostafaTherapeutics Research Centre, Translational Research Institute, University of Queensland, Brisbane, Australia; ;Pharmaceutical Chemistry Department, Helwan University, Helwan, Egypt;

Ana SaiaoClinical Toxicology Research Group, University of Newcastle, Newcastle, Australia;

Jeffrey E. GriceTherapeutics Research Centre, Translational Research Institute, University of Queensland, Brisbane, Australia;

Michael S. RobertsTherapeutics Research Centre, Translational Research Institute, University of Queensland, Brisbane, Australia; ;School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

Geoffrey K. IsbisterClinical Toxicology Research Group, University of Newcastle, Newcastle, Australia;

Abstract

Objective: To describe the cardiovascular toxicity and pharmacokinetics of levetiracetam in overdose. Case Report: A 43-year-old female presented 8 h post ingestion of 60–80 g of levetiracetam with mild central nervous system depression, bradycardia, hypotension and oliguria. Her cardiovascular toxicity transiently responded to atropine and intravenous fluids. A bedside echocardiogram demonstrated normal left and right ventricular contractility. Despite her cardiovascular toxicity and oliguria, she had normal serial venous lactates and renal function; and made a complete recovery over 48 h. Her levetiracetam concentration was 463 mcg/ml 8 h post ingestion (therapeutic range 10–40 mcg/ml) and her concentration–time data best fitted a one-compartment model with first-order input and an elimination half-life of 10.4 h. Discussion: Levetiracetam in large ingestions appears to cause bradycardia and hypotension that is potentially responsive to atropine and intravenous fluids. Based on a normal echocardiogram, the mechanism for this effect may be levetiracetam acting at muscarinic receptors at high concentration. The pharmacokinetics of levetiracetam in overdose appeared to be similar to therapeutic levetiracetam dosing.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cardiovascular toxicity with levetiracetam overdose

Information for

Open access

Opportunities

Help and information

Cardiovascular toxicity with levetiracetam overdose

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature